Stoke Therapeutics (STOK) Operating Margin (2022 - 2025)
Historic Operating Margin for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to 405.3%.
- Stoke Therapeutics' Operating Margin rose 2077600.0% to 405.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.23%, marking a year-over-year increase of 7138300.0%. This contributed to the annual value of 277.31% for FY2024, which is 10299000.0% up from last year.
- According to the latest figures from Q3 2025, Stoke Therapeutics' Operating Margin is 405.3%, which was up 2077600.0% from 197.58% recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' Operating Margin registered a high of 70.15% during Q1 2025, and its lowest value of 1340.67% during Q2 2023.
- Over the past 4 years, Stoke Therapeutics' median Operating Margin value was 672.96% (recorded in 2024), while the average stood at 637.29%.
- Per our database at Business Quant, Stoke Therapeutics' Operating Margin plummeted by -5595500bps in 2023 and then skyrocketed by 9955100bps in 2024.
- Quarter analysis of 4 years shows Stoke Therapeutics' Operating Margin stood at 831.58% in 2022, then dropped by -27bps to 1055.89% in 2023, then surged by 94bps to 60.37% in 2024, then plummeted by -571bps to 405.3% in 2025.
- Its last three reported values are 405.3% in Q3 2025, 197.58% for Q2 2025, and 70.15% during Q1 2025.